Drugs / MMRV (2006 process)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01536405 Comparator | Jun 2012 → Jul 2013 | chickenpox, measles, mumps infectious disease, rubella | Merck Sharp & Dohme LLC | Completed | Mixed |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMRV (2006 process) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01536405 ↗ |
| Known as | MMRV | “Healthy children 12-to-23 months of age at 71 US sites were randomized (1:1) to receive MMRV manufactured using an alternative process (MMRVAMP) or the currently licensed MMRV.” PMID 27149048 ↗ May 2016 |
| Modality | Vaccine | “MMRV vaccine” NCT01536405 ↗ |
| Route | Subcutaneous | “two 0.5 mL subcutaneous injections” NCT01536405 ↗ |